X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
GlycoProteMim (TFC-1326) is Sirona’s lead anti-aging compound, a topical cream small molecule drug candidate, with potential to reverse the effects of aging on facial skin, restoring lost volume and reducing fine wrinkles.
Lead Product(s): TFC-1326
Therapeutic Area: Dermatology Product Name: GlycoProteMim
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2023
Details:
TFC-1326 is Sirona’s lead anti-aging compound, will soon enter a clinical trial designed to assess its potential to reverse the effects of aging on facial skin, restoring lost volume and reducing fine wrinkles.
Lead Product(s): TFC-1326
Therapeutic Area: Dermatology Product Name: TFC-1326
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2023
Details:
The ICGEB has successfully screened a library of 20 compounds produced at Sirona’s subsidiary TFChem as potential inhibitors of SARS-CoV-2 using specialized assays developed at the centre.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2023
Details:
The formulation is a cream base with TFC-1326 at a concentration of 1% and no other active ingredients. The trial is designed to assess the compound’s efficacy in reversing aging facial skin, including restoring lost volume (plumping) and reducing fine wrinkles.
Lead Product(s): TFC-1326
Therapeutic Area: Dermatology Product Name: TFC-1326
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2022
Details:
Under the agreement, Wanbang obtained the rights to develop the SGLT2 inhibitor, TFC-039 as a diabetes treatment in China and Sirona retained the global rights. SGLT2 inhibitors provide an opportunity to treat inflicted animals with an oral medication.
Lead Product(s): TFC-039
Therapeutic Area: Endocrinology Product Name: TFC-039
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Wanbang Biopharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 23, 2022
Details:
TFC-1326 1% in formulation is a non-irritant and non-sensitizer, a claim recognized in the industry based on these results and accepted by global regulatory bodies.
Lead Product(s): TFC-1326
Therapeutic Area: Dermatology Product Name: TFC-1326
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2022
Details:
Scientists at ICGEB will test the potential antivirals against SARS-CoV-2 (COVID-19) using specialized assays developed at the centre.
Lead Product(s): Antiviral Therapeutics
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: International Centre for Genetic Engineering and Biotechnology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 10, 2022
Details:
TFC-1326 has the potential to replace or supplement dermal filler injections to treat the static wrinkles. TFC-1326 with its unique mechanism of action is revolutionary in the aesthetic skin care space.
Lead Product(s): TFC-1326
Therapeutic Area: Dermatology Product Name: TFC-1326
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: WuXi AppTec Inc.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 22, 2022
Details:
Under Licensing agreement with Sirona, pursuant to which Allergan Aesthetics will develop and commercialize topical skin care treatments based on active ingredients derived from certain of Sirona’s patents for TFC-1067 (Difluorocyclohexyloxyphenol) and related compounds.
Lead Product(s): Difluorocyclohexyloxyphenol
Therapeutic Area: Dermatology Product Name: TFC-1067
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Allergan Aesthetics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 13, 2022
Details:
Under the terms of the agreement, Sirona will manufacture and supply TFC-1067 (difluorocyclohexyloxyphenol), a novel, new skin brightening ingredient, for use by Rodan + Fields on a non-exclusive basis and Rodan + Fields will launch a new product incorporating the ingredient.
Lead Product(s): Difluorocyclohexyloxyphenol
Therapeutic Area: Dermatology Product Name: TFC-1067
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: RODAN & FIELDS LLC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination January 16, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
